Response Pharmaceuticals

Response Pharmaceuticals is a clinical-stage (Phase 2) company with a focus on developing treatments for weight management and metabolic health. The company's lead asset, RDX-002, is a first-in-class weight management and cardiometabolic health drug with confirmed efficacy and safety in >550 subjects. The initial focus of Response Pharmaceuticals is to address the underserved patient populations taking antipsychotic medications for disabling mental illnesses, aiming to combat weight gain and metabolic dysregulation associated with these treatments. The company is tackling the issue of antipsychotic-induced weight gain (AIWG), which is pervasive among individuals with severe mental illness, contributing to a growing mortality gap between this population and the general population. Additionally, RDX-002 is being evaluated in other settings with prevalent clinically significant weight gain and/or adverse metabolic changes. Founded in 2021, Response Pharmaceuticals operates in the Biopharma, Biotechnology, and Pharmaceutical industries. The company recently received an $8.00M Series A investment on 23 February 2022 from investors including STONEHAVEN, LLC, Flying Cloud Securities, and Collage Partners LLC. This investment will likely support the advancement of the company's clinical programs and further development of its lead asset. Overall, Response Pharmaceuticals is positioned to address a critical and underserved medical need, making it an attractive prospect for venture capital investment in the biopharmaceutical space.